OverviewSuggest Edit

Predictive Oncology (formerly Precision Therapeutics and Skyline Medical) is a medical device company. It provides an environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The company offers the STREAMWAY Fluid Waste Management System that suctions surgical waste fluid from the patient using standard surgical tubing. 

TypePublic
Founded2002
HQEagan, US
Websitepredictive-oncology.com

Latest Updates

Employees (est.) (Dec 2018)24(+42%)
Revenue (FY, 2019)$1.4 M
Share Price (Sept 2020)$0.8 (-1%)
Cybersecurity ratingAMore

Key People/Management at Predictive Oncology

Carl Schwartz

Carl Schwartz

Interim President and Cheif Executive Officer, Director
David Johnson

David Johnson

COO
Bob Myers

Bob Myers

CFO
David Dauwalter

David Dauwalter

Director of Product Management
Rodney Schmidt

Rodney Schmidt

Senior Design Engineer
Show more

Predictive Oncology Office Locations

Predictive Oncology has an office in Eagan
Eagan, US (HQ)
2915 Commers Dr #900
Show all (1)

Predictive Oncology Financials and Metrics

Predictive Oncology Revenue

Embed Graph
View revenue for all periods
Predictive Oncology's revenue was reported to be $1.41 m in FY, 2019
USD

Revenue (Q2, 2020)

182.8k

Gross profit (Q2, 2020)

97.5k

Gross profit margin (Q2, 2020), %

53.4%

Net income (Q2, 2020)

(3.6m)

EBIT (Q2, 2020)

(3.8m)

Market capitalization (22-Sept-2020)

13.0m

Closing stock price (22-Sept-2020)

0.8

Cash (30-Jun-2020)

3.4m

EV

15.6m
Predictive Oncology's current market capitalization is $13 m.
USDQ2, 2011

Debt/Equity

-0.3 x

Debt/Assets

2.6 x

Financial Leverage

-0.1 x
Show all financial metrics

Predictive Oncology Acquisitions / Subsidiaries

Company NameDateDeal Size
CytoBioscienceAugust 01, 2017

Predictive Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Predictive Oncology Online and Social Media Presence

Embed Graph

Predictive Oncology News and Updates

Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time

EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor …

Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intelligence?’

LOS ANGELES, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of…

Predictive Oncology Completes Acquisition of Quantitative Medicine

Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development

Predictive Oncology Reports First Quarter 2020 Financial Results, Provides Business Update

CancerQuest 2020 Study on Schedule for Completion in Q2 2020 CancerQuest 2020 Study on Schedule for Completion in Q2 2020

Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech

MINNEAPOLIS, June 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of Soluble…

Predictive Oncology Reports 2019 Full-year Financial Results

MINNEAPOLIS, April 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for its full…
Show more

Predictive Oncology Blogs

Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Media

A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient Derived Sample. MINNEAPOLIS , June 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.

Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development

Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development Content Import Thu, 05/14/2020 - 08:31 Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 t…

Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Content Import Thu, 05/07/2020 - 08:03 Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules May 7, 2020 …

Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10

MINNEAPOLIS , May 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr.

Predictive Oncology Exchanges $2.1 Million of Debt for Equity, Streamlining Capital Structure and Simplifying Balance Sheet

CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future NEW YORK , April 22, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that it has entered into an Exchange Agreement relating to a $2.1 million

Predictive Oncology (NASDAQ: POAI) CEO Discusses ‘Major Asset’ in Exclusive Interview

NEW YORK , April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz , in an interview with NetworkNewsWire (NNW), discussed the Predictive Oncology’s distinctive business model and significant
Show more

Predictive Oncology Frequently Asked Questions

  • When was Predictive Oncology founded?

    Predictive Oncology was founded in 2002.

  • Who are Predictive Oncology key executives?

    Predictive Oncology's key executives are Carl Schwartz, David Johnson and Bob Myers.

  • How many employees does Predictive Oncology have?

    Predictive Oncology has 24 employees.

  • What is Predictive Oncology revenue?

    Latest Predictive Oncology annual revenue is $1.4 m.

  • What is Predictive Oncology revenue per employee?

    Latest Predictive Oncology revenue per employee is $58.8 k.

  • Who are Predictive Oncology competitors?

    Competitors of Predictive Oncology include 19Labs, StarFish Medical and Vapotherm.

  • Where is Predictive Oncology headquarters?

    Predictive Oncology headquarters is located at 2915 Commers Dr #900, Eagan.

  • Where are Predictive Oncology offices?

    Predictive Oncology has an office in Eagan.

  • How many offices does Predictive Oncology have?

    Predictive Oncology has 1 office.